Shuxuan Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shuxuan Wu has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Rong Mei
Department of Anesthesiology, Jinlong hospital, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi City, Hubei Province, China
1 shared publicationWei Zhang
Department of Anesthesiology, Jinlong hospital, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi City, Hubei Province, China
1 shared publication
Latest Publications
- 11 April 2022
- Published by Taylor & Francis in Bioscience, Biotechnology, and Biochemistry
- Vol. 86 (7) , 837-845
Ketorolac tromethamine represses senescence in aging articular chondrocytes
The present study aims to explore the potential function of ketorolac tromethamine in treating osteoarthritis (OA) by examining its effects on interleukin-1β (IL-1β)-triggered cellular senescence in chondrocytes. More β-galactosidase (SA-β-Gal) positively stained cells, promoted cell fraction in the G0/G1 phase, increased release of matrix metalloproteinase (MMP)-3 and MMP-13, and upregulated cellular senescence-related genes (p21 and p53) were observed in IL-1β-challenged HC-A cells, all of which were significantly reversed by 25 and 50 mg/mL ketorolac tromethamine. Furthermore, the upregulated cyclooxygenase-2 (COX-2) and elevated release of prostaglandin E2 (PGE2) in IL-1β- challenged HC-A cells were dramatically repressed by ketorolac tromethamine. Lastly, the inhibitory effects of ketorolac tromethamine on the activation of β-galactosidase and the upregulation of p21 and p53 were greatly abolished by the overexpression of COX-2. Collectively, ketorolac tromethamine repressed cellular senescence in aging articular chondrocytes by inhibiting COX-2.
- 11 April 2022
- Published by Taylor & Francis in Bioscience, Biotechnology, and Biochemistry
- Vol. 86 (7) , 837-845
Ketorolac tromethamine represses senescence in aging articular chondrocytes
The present study aims to explore the potential function of ketorolac tromethamine in treating osteoarthritis (OA) by examining its effects on interleukin-1β (IL-1β)-triggered cellular senescence in chondrocytes. More β-galactosidase (SA-β-Gal) positively stained cells, promoted cell fraction in the G0/G1 phase, increased release of matrix metalloproteinase (MMP)-3 and MMP-13, and upregulated cellular senescence-related genes (p21 and p53) were observed in IL-1β-challenged HC-A cells, all of which were significantly reversed by 25 and 50 mg/mL ketorolac tromethamine. Furthermore, the upregulated cyclooxygenase-2 (COX-2) and elevated release of prostaglandin E2 (PGE2) in IL-1β- challenged HC-A cells were dramatically repressed by ketorolac tromethamine. Lastly, the inhibitory effects of ketorolac tromethamine on the activation of β-galactosidase and the upregulation of p21 and p53 were greatly abolished by the overexpression of COX-2. Collectively, ketorolac tromethamine repressed cellular senescence in aging articular chondrocytes by inhibiting COX-2.